Milestone Pharmaceuticals (MIST) Non-Current Debt (2023 - 2026)

Milestone Pharmaceuticals' Non-Current Debt history runs 4 years deep, the most recent figure standing at $58.2 million for Q1 2026.

• Quarterly Non-Current Debt rose 7.19% year-over-year to $58.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.2 million (up 7.19% YoY) and the FY2025 annual result came in at $57.2 million, up 7.2% from the prior year.
• Non-Current Debt was $58.2 million for Q1 2026 at Milestone Pharmaceuticals, up from $57.2 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $58.2 million in Q1 2026 and bottomed at $47.3 million in Q1 2023.
• A 4-year average of $52.6 million and a median of $52.4 million in 2024 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2024 — Non-Current Debt grew 7.02% — and 2025, when it rose 7.2%.
• Milestone Pharmaceuticals' Non-Current Debt stood at $49.8 million in 2023, then increased by 7.19% to $53.4 million in 2024, then advanced by 7.2% to $57.2 million in 2025, then increased by 1.75% to $58.2 million in 2026.
• Business Quant data shows MIST's Non-Current Debt at $58.2 million in Q1 2026, $57.2 million in Q4 2025, and $56.2 million in Q3 2025.